CML-413 Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial

Medicine & Life Sciences

• bosutinib 100%
• Imatinib Mesylate 67%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62%
• Safety 34%
• Leukemia, Myeloid, Chronic Phase 20%
• Nausea 8%
• Fatigue 8%
• Diarrhea 8%
• Therapeutics 7%
• Philadelphia Chromosome 6%
• Population 5%
• Lipase 5%
• Spasm 5%
• Constipation 5%
• Exanthema 4%
• Alanine Transaminase 4%
• Standard of Care 4%
• Thrombocytopenia 4%
• Duration of Therapy 4%
• Multicenter Studies 4%
• Headache 4%
• Edema 4%
• Health Care Outcome Assessment 3%
• Databases 2%